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Note: GeneLoc location for GC13M032575: Start: 
32,575,307bp from pter; End: 32,757,892; Size: 
182,585; Orientation: minus strand. 
Description 
DLC2 was identified due to striking sequence 
homology to DLC1. It localizes to a small region of 
13q12.3, which is a locus frequently deleted in 
hepatocellular carcinoma (HCC) as well as in other 
cancers. Physical mapping of DLC2 in human genome 
revealed that it is in close proximity to the BRCA2 
locus and flanked by microsatellite markers D13S171 
and D13S267. The human DLC2 gene spans a region 
of 182 kb and contains 14 coding exons. 
Transcription 
The mRNA of DLC2 is 5886 bp long with an open 
reading frame of 3342 bp. Using bioinformatic 
analysis, 4 isoforms of DLC2, namely, DLC2alpha 
(5886 bp), DLC2beta (5810 bp), DLC2gamma (5784 
bp), and DLC2delta (943 bp) have been identified. 
These 4 isoforms are generated by alternative splicing 
of the 5' end of the transcript. Northern blot analysis 
detected 7.2- and 4.2-kb DLC2 transcripts in all tissues 
examined, with the highest expression in heart, skeletal 
muscle, kidney, and pancreas. 
 
Genomic characterization of human DLC2. (A) chromosomal map location of human DLC2 at 13q 12.3. Arrows underneath the gene 
symbols indicate the orientation of transcription. RFC3, replication factor C subunit 3; KL, Klotho; AS3, androgen shutoff 3; BRCA2, 
breast cancer 2, early onset; Tel, telomeric; Cen, centromeric. (B) genomic organization of human DLC2 locus. Non-coding (open 
boxes) and coding (filled boxes) are shown. (Ching YP,et al. J Biol Chem 2003). 
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Protein 
Description 
DLC2alpha encodes a 1113-amino acid protein which 
has a calculated molecular mass of 125 kD. DLC2 
contains an N-terminal sterile alpha motif (SAM) 
domain for protein-protein interactions, followed by an 
ATP/GTP-binding motif, a GTPase-activating protein 
(GAP) domain, and a C-terminal STAR-related lipid 
transfer (START) domain. The 4 isoforms of DLC2, 
DLC2alpha, DLC2beta, DLC2gamma, and DLC2delta, 
encode proteins of 1113, 1105, 995, and 135 amino 
acids, respectively. DLC2alpha and DLC2beta encode 
a protein containing three functional domains, SAM, 
RhoGAP and START domains. DLC2alpha and 
DLC2beta differ by only a few N-terminal amino acids. 
DLC2gamma contains the RhoGAP and START 
domains, but lacks the N-terminal SAM domain, 
whereas DLC2delta contains only the SAM domain. 
Co-immunoprecipitation assay of ectopically expressed 
DLC2 in cells revealed that DLC1 forms homodimers 
in vivo and the region 160-672 residues is responsible 
for the interaction. 
Expression 
DLC2 is ubiquitously expressed in human tissues and is 
more abundant in heart, skeletal muscle, kidney and 
pancreas. 
Localisation 
DLC2alpha, DLC2beta and DLC2gamma are 
predominantly localized in the cytoplasm in mouse  
fibroblast and human HCC cells. Cellular fractionation 
and immunofluorescence microscopy revealed that 
DLC2 localizes to cytoplasmic speckles overlapping 
with mitochondria and in structures in close proximity 
to lipid droplets. The START domain of DLC2 has 
been demonstrated to be responsible for mitochondria 
targeting of DLC2. 
Function 
DLC2 has been implicated to be a tumor suppressor 
protein. DLC2 has growth suppressive and anti-
metastatic effects on HCC cell line, HepG2 and breast 
cancer cell line, MCF7. The RhoGAP domain has been 
demonstrated to be responsible for its biological 
functions and the RhoGAP activity has been 
demonstrated in vitro and in vivo. Recombinant DLC2 
showed GAP activity specific for small GTPases, 
RhoA and Cdc42. Using GST-Rhoteckin pull down 
assay, in vivo RhoA activity has been shown to be 
negatively regulated by DLC2. However, in cells  
transfected with DLC2 RhoGAP mutant, the in vivo 
RhoA activity remained unchanged. Moreover, DLC2 
inactivates RhoA activity via its RhoGAP domain and 
leads to the inhibition of actin stress fiber formation. 
Ectopic expression of DLC2 changed mouse fibroblast 
morphology from angular and spindle-shaped to round-
shaped with dendritic cellular protrusions. Cells 
express DLC2 RhoGAP mutants did not exhibit 
morphological change and the actin stress fiber 
formation in these cells is unaffected. Introduction f 
human DLC2 into mouse fibroblasts suppressed Ras 
signaling and Ras-induced cellular transformation in a 
GAP-dependent manner. Overexpression of DLC2 also 
 
A. DLC2 is a multifunctional protein. Diagram of protein domains in DLC2. SAM, sterile alpha motif; ATP/GTP binding, ATP/GTP-binding 
site motif A; GAP, RhoGAP domain; START, StAR-related lipid transfer domain. (Ching YP,et al. J Biol Chem 2003). 
B. Functional domains of the DLC2 isoforms. DLC2alpha and DLC2beta each contains a SAM, a RhoGAP, and a START domain, but 
they differ in their N-terminal sequence. The difference in the amino acid sequence was located at the first 60 aa in DLC2alpha and the 
first 52 aa in DLC2beta. DLC2gamma contains a RhoGAP and a START domain. DLC2delta only contains a SAM domain. (Leung TH, 
et al. Proc Nat Acad Sci USA. 2005). 
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suppressed cell proliferation, motility and anchorage-
independent growth in human hepatoma cells. 
Collectively, down regulation of RhoA activity in HCC 
cell line by DLC2 resulted in change of cell 
morphology, migration rate, proliferation rate and 
transforming ability. 
Several proteins were identified as interacting partners 
of DLC2 by yeast two-hybrid screening. These proteins 
include SWI/SNF, alpha-tubulin, HMG CoA reductase, 
and TAX1 binding protein (TAX1BP1). 
Homology 
DLC family members: DLC1 is located at chromosome 
8p22; DLC3 is located at chromosome Xq13; DLC2 
shares 51% and 52% amino acid identities with DLC1 
and DLC3, respectively. 
Implicated in 
Cancer 
Note: DLC2, with its RhoGAP domain, is able to 
inhibit the activity of RhoA, which is believed to play a 
significant role in cell transformation in many caner 
types. Down regulation of DLC2 mRNA expression 
has been reported in various types of cancer including 
liver, breast, lung, ovarian, renal, uterine, gastric, colon 
and rectal tumors. 
DLC2 localizes to a small region of 13q12.3 commonly 
deleted in HCC. DLC2 is flanked by microsatellite 
markers D13S171 and D13S267. Loss of 
heterozygosity on these two markers is frequently 
found in HCC. Allelic losses at markers D13S171 and
D13S267 are detected in 33.3% and 40.7% of the 
informative cases, respectively. RT-PCR analysis of 
DLC2 mRNA in 45 HCC samples revealed that 17.8% 
of the cases showed significant underexpression (more 
than 2-fold) of DLC2 mRNA when compared with the 
corresponding non-tumorous liver tissues from the 
same patients. 
Studies in human cancers have suggested that small 
GTPases of the Rho family are critically involved 
tumorigenesis. Suppression of RhoA activity may be 
able to reverse the transformation phenotype in cancers. 
RhoGAP activity of DLC2 has been demonstrated both 
in vitro and in vivo. Anchorage-independent growth of 
cancer cells is a hallmark of cellular transformation. 
Stable expression of DLC2 in liver cancer cell line  
effectively abolished the anchorage-independent 
growth ability of the cells. This indicated that DLC2 is 
capable of reducing the transforming phenotype and 
supports the view that DLC2 is a functional tumor 
suppressor. 
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